April 20, 2017 — iCAD Inc. announced that updated clinical data on the use of intraoperative radiation therapy (IORT) using the Xoft Axxent Electronic Brachytherapy (eBx) System will be presented during the American Brachytherapy Society (ABS) Annual Meeting, April 21-22 in Boston. The Xoft System and its suite of products will also be showcased at the Xoft booth.
At the meeting, Gary Proulx, M.D., medical director, radiation oncology at Exeter Hospital (N.H.) will present updated findings on his recent clinical experience treating 94 early-stage breast cancer patients with IORT using the Xoft System. The snap oral presentation is entitled “Intraoperative Radiation (IORT) as Adjuvant Radiation Monotherapy for Early-Stage Breast Cancer Patients Treated with Breast Conserving Surgery.”
“Early results from our research suggest that this short course of full-dose radiation in a single treatment offers a low rate of local failure and a high rate of excellent cosmesis for properly selected patients. We are happy to report that 100 percent of patients were very pleased with the treatment experience and treatment outcome on follow up visits,” said Proulx. “I am very encouraged by the early results of our research that indicate improved quality of life for patients eligible for IORT by greatly reducing the number of treatments patients receive when compared to EBRT.”
In addition, Ajay Bhatnagar, M.D., MBA, radiation oncologist at 21st Century Oncology (Ariz.), will participate in a panel discussion and several workshops during the meeting to review his recent clinical experience in treating nonmelanoma skin cancer (NMSC) with the Xoft System.
The Xoft System is an isotope-free radiation treatment that is FDA cleared, CE marked, and licensed in a growing number of countries for the treatment of cancer anywhere in the body, including treatment of early-stage breast cancer, gynecological cancers and non-melanoma skin cancer. It utilizes a proprietary miniaturized X-ray as the radiation source that delivers precise treatment directly to cancerous areas while sparing healthy tissue and organs. The system requires only minimal shielding and therefore does not require room redesign or construction investment. Minimal shielding also allows medical personnel to remain in the room with the patient during treatment. The mobility of the Xoft System makes it easy to treat patients at multiple locations and to easily store the system when not in use.
For more information: www.xoftinc.com
April 16, 2024 
